Such findings clearly demonstrate that targeting CD39, either alone or in conjunction with anti-PD-1, is efficient in correcting the mal-differentiation of T cells and enhancing anti-tumor T cell responses in NSCLC patients. This evidence concerns the gene ENTPD1 and neoplasm.